Read our latest press releases, financial reports, and annual meeting materials.
Ortivus shares have been listed on the NASDAQ Stockholm Small Cap-lista since January 2, 1997.
The share capital is SEK 15,507,614. Share capital is divided between class A and class B shares. The number of shares outstanding is 44,307,468 of which class A amount to 1,662,682 and class B to 42,644,786. Every class A share carries 10 votes and every class B share carries one vote.
Hover the mouse over the graphs to see the share price at the corresponding date.
Stock Symbol | ISIN | Shares Outstanding | Votes/share | Total Number of Votes | |
---|---|---|---|---|---|
Class A | ORTI A | SE0000188930 | 1,662,682 | 10 | 16,626,820 |
Class B | ORTI B | SE0000123085 | 42,644,786 | 1 | 42,644,786 |
Ortivus A
Ortivus B
Top 10 Shareholders as per 30th of September 2020
Number of shares | Share of Capital | ||
---|---|---|---|
PONDERUS INVEST AB | Series A Series B Total | 13 177 10 360 762 10 373 939 | 23.3% |
NORDNET PENSIONSFÖRSÄKRING A | Series A Series B Total | 33 593 3 955 703 3 989 296 | 9.0% |
FÖRSÄKRINGS AB AVANZA | Series A Series B Total | 54 299 3 711 161 3 765 460 | 8.5% |
PETTERSSON, RUNE | Series B | 2 802 620 | 6.3% |
FRAIM, ING-MARIE | Series B | 1 974 087 | 4.5% |
RASPART FÖRVALTNING AB | Series B | 1 850 418 | 4.2% |
ADOLFSSON, PER-OLA | Series B | 1 597 963 | 3.6% |
SELIGSON & CO PHOENIX FUND | Series B | 1 554 795 | 3.5% |
ERIKSSON, NILS-ARNE | Series B | 1 550 625 | 3.5% |
GAGAB AB | Series B | 824 659 | 1.9% |
Sum of top 10 shareholders | 68.4% |
- Ortivus protokoll årsstämma 2019
- Ortivus protokoll årsstämma 2019 bilagor 2-4
- Ersättning till ledande befattningshavare revisorns yttrande
- Fullmaktsblankett
- Kallelse till årsstämma i Ortivus AB
- Ortivus styrelsen redovisning av resultatet av ersättningskommitten
- Ortivus valberedningens arbete 2019
- Ortivus valberedningens motiverade yttrande 2019
- Styrelsens förslag till riktlinjer för ersättning till ledande befattningshavare
18-01-2023
As previously reported, Ortivus AB signed a Letter of Intent in December 2022 with technology
Read more
15-12-2022
We are very pleased to announce that the Estonian Health Insurance Fund Haigekassa has decided
Read more
14-12-2022
Ortivus AB has signed a Letter of Intent with the technology company H&E Solutions AB.
Read more
06-12-2022
Ortivus has received an order from Jersey Ambulance Service regarding the delivery of MobiMed ePR
Read more
28-11-2022
Ortivus has been awarded a contract for the delivery of pre-hospital electronic patient record, case
Read more
11-11-2022
Ortivus continues to gain market share and component shortages affect deliveries
Read more
25-10-2022
Ortivus is pleased to announce that the company is starting the Danish subsidiary Ortivus MobiMed
Read more
10-10-2022
Ortivus is happy to announce that the company enters a strategic distribution partnership with the
Read more
The board of Ortivus AB (publ) has decided to carry out a 100% secured rights issue of approximately SEK 9 million. The Board’s decision is conditional on the approval of the forthcoming Extraordinary General Meeting, which will be held on February 18, 2019. The proposed pre-emptive share issue intends to improve the Company’s financial position while allowing for continued development of the Company’s operations.
(Documents below are in Swedish only)
The Board of Directors of Ortivus AB (publ) has, on the basis of authorization from the Annual General Meeting 2019, decided on a new issue comprising 7,500,000 new B shares directed at a small number of specially selected investors. The total share issue raises SEK 15 million before costs for issuing of new shares. The new shares are issued at a subscription price corresponding to SEK 2 per share. The subscription price has been determined on a market basis and corresponds to the volume-weighted price of the company’s B shares during the last 20 trading days with a mark-up of 5%. The investors who signed up for the directed new share issue have undertaken not to sell the newly issued shares within 6 months from the Board’s decision, so-called Lock-up. The rights issue is carried out with the aim of securing further financing of the company’s working capital and the continued development of the company’s operations.
Download the prospectus (in Swedish) “Ortivus-AB-(publ)_Prospekt-avseende-upptagande-till-handel-av-nyemitterade-aktier_2019-07-10” here.